Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

NCT02921269 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

11

Enrollment

NIH

Sponsor class

Conditions

Cervical Adenocarcinoma
Cervical Adenosquamous Carcinoma
Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Recurrent Cervical Carcinoma
Stage IV Cervical Cancer AJCC v6 and v7
Stage IVA Cervical Cancer AJCC v6 and v7
Stage IVB Cervical Cancer AJCC v6 and v7

Interventions

DRUG: Atezolizumab
BIOLOGICAL: Bevacizumab
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)